Sahara News
Breaking News in Nigeria and World wide

COVID-19 vaccine: SA weighs options to sell or swap AstraZeneca shots ahead of J&J rollout

South Africa’s wellbeing priest Zweli Mkhize said on Wednesday the public authority may sell or trade portions of AstraZeneca’s Covid-19 antibody it may not need, as it scrambles to begin immunizing its residents with an elective US shot one week from now.

South Africa stopped the rollout of the antibody created by AstraZeneca and Oxford University following information in a little clinical preliminary that indicated it didn’t shield against mellow to direct ailment from the 501Y.V2 variation of the Covid now prevailing in the country.

ALSO READ:  BREAKING:FG Declares September 16 As National Identity day.

1,000,000 dosages of the AstraZeneca immunization, delivered by the Serum Institute of India, arrived in the country a week ago, and another 500 000 are expected to show up in coming weeks. That is sufficient to vaccinate 750 000 individuals.

Mr. Mkhize told a news meeting on Wednesday that the nation would begin immunizing wellbeing laborers with Johnson and Johnson’s immunization as an “usage study” with specialists some time one week from now.

ALSO READ:  BREAKING:Group Asks National Assembly To Speed Up Passage Of Electoral Bill

He said he would sit tight for counsel from researchers prior to continuing with the conceivable deal or switch of the British shot.


The wellbeing clergyman said he would talk about a proposition to trade 500 000 portions from Serum that have not yet been conveyed with COVAX, which has tied down large supplies of the went for dissemination to helpless countries.

The move is the most recent turn in an adventure that has overwhelmed the South African government this week as it scrambles to tame the quick spreading variation. The country’s loss of life is approaching 47,000 and diseases have outperformed 1.47-million.

ALSO READ:  REVEALED:What Nigerian Government Must Do To Stop Banditry — Obasanjo, Sheikh Gumi

Get real time updates directly on you device, subscribe now.

Leave A Reply

Your email address will not be published.

error: Content is protected !!